Abstract Number: 1807 • 2017 ACR/ARHP Annual Meeting
Psychometric Evaluation of the Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) in Inflammatory Arthritis
Background/Purpose: The Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) is a recently developed patient reported outcome measure (PROM) for use across patients with different musculoskeletal…Abstract Number: 1808 • 2017 ACR/ARHP Annual Meeting
Long-Term Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in Patients with Systemic Lupus Erythematosus
Background/Purpose: To report the 5-year immunogenicity of a quadrivalent human papillomavirus (HPV) vaccine (GARDASIL) in patients with systemic lupus erythematosus (SLE). Methods: Female SLE patients…Abstract Number: 1809 • 2017 ACR/ARHP Annual Meeting
Lack of Placental Transfer of Certolizumab Pegol during Pregnancy: Results from a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study
Background/Purpose: There is a need for effective and safe treatment during pregnancy in women affected by chronic active inflammatory diseases such as rheumatoid arthritis. Adequate…Abstract Number: 1810 • 2017 ACR/ARHP Annual Meeting
A Systematic Review of the Impact of Anti-Rheumatic Drugs upon Male Fertility and Paternal Exposure Peri-Conception
Background/Purpose: There is limited evidence relating to the impact of disease modifying anti-rheumatic drugs (DMARDs) upon male fertility and on pregnancies conceived by men with rheumatic…Abstract Number: 1811 • 2017 ACR/ARHP Annual Meeting
Lupus Patients, and Their Sisters, Have Higher Miscarriage Rates Than Healthy Women
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that primarily affects women during the childbearing years. Among its protean manifestation, pregnancy complications including…Abstract Number: 1812 • 2017 ACR/ARHP Annual Meeting
Preeclampsia and Incident Cardiovascular Disease in SLE Pregnancy
Background/Purpose: Pre-pregnancy cardiovascular health has been associated with preeclampsia during pregnancy, as well as future cardiovascular disease (CVD). Preeclampsia is related to endothelial dysfunction, hypertension,…Abstract Number: 1813 • 2017 ACR/ARHP Annual Meeting
Rates of Contraceptive Use and Unintended Pregnancy in Teen Girls Prescribed Teratogenic Medications
Background/Purpose: Reproductive aged women with rheumatic diseases are often prescribed teratogenic medications. These medications pose a serious threat to the mother and fetus. Rates of…Abstract Number: 1814 • 2017 ACR/ARHP Annual Meeting
Time Trends over a Decade Show Earlier Intensified Medication Strategies and Improved Outcomes in Canadians with Early Inflammatory Arthritis
Background/Purpose: Treatment recommendations aim to improve outcomes in rheumatoid arthritis (RA) through early identification and a treat-to-target approach. We examined recent trends over the past…Abstract Number: 1815 • 2017 ACR/ARHP Annual Meeting
Patterns of Methotrexate Use and Discontinuation in a U.S. Rheumatoid Arthritis Registry
Background/Purpose: Methotrexate (MTX) remains a cornerstone therapy in the management of rheumatoid arthritis (RA), but patterns of adherence, intolerance, and inadequate response are not well…Abstract Number: 1816 • 2017 ACR/ARHP Annual Meeting
Sex Differences in Orthopedic Surgery Among Patients with Rheumatoid Arthritis
Background/Purpose: Despite a decline in the incidence of orthopedic surgeries for rheumatoid arthritis (RA) in recent years, joint replacement remains an option for patients with…Abstract Number: 1817 • 2017 ACR/ARHP Annual Meeting
Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry
Background/Purpose: In the absence of biomarkers predicting response to a specific therapy, the choice of second biologic is based mostly on habit and availability of…Abstract Number: 1818 • 2017 ACR/ARHP Annual Meeting
Development of Abatacept- and Adalimumab-Specific Predictive Models of Response to Therapy in RA Using Data from a Head-to-Head Study
Background/Purpose: Highly effective, targeted DMARD therapies with different mechanisms of action are available for RA. Translating precision medicine into clinical practice requires treatment-specific predictive models,…Abstract Number: 1819 • 2017 ACR/ARHP Annual Meeting
Delay of Diagnosis and Treatment in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity
Background/Purpose: Evidence supports a therapeutic window of opportunity in early rheumatoid arthritis (RA), during which DMARD therapy most effectively improves clinical outcomes. The 2010 ACR/EULAR…Abstract Number: 1820 • 2017 ACR/ARHP Annual Meeting
Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years
Background/Purpose: Remission induction with methotrexate (MTX) and a moderate-dose, step-down scheme of Glucocorticoids (GC), (COBRA Slim strategy), showed equally high remission rates at year 1…Abstract Number: 1821 • 2017 ACR/ARHP Annual Meeting
Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study
Background/Purpose: In patients (pts) with active RA and inadequate response (IR) to DMARDs, phase 3 studies demonstrated efficacy of baricitinib (2-mg and 4-mg). Larger, more…
ACR Meeting Abstracts